These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31159876)

  • 41. Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
    Alentorn A; Durán-Peña A; Malousi A; Marie Y; Mokhtari K; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A; Vecht C
    J Neurooncol; 2015 Sep; 124(3):385-92. PubMed ID: 26224161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
    J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
    Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
    Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oligonucleotide DNA chips are useful adjuncts in epigenetic studies of glioblastomas.
    Kim B; Kim H; Song BJ; Cha SH; Lee MO; Park SH
    Neuropathology; 2006 Oct; 26(5):409-16. PubMed ID: 17080717
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
    Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
    Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
    Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
    J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
    Rösche J; Piek J; Hildebrandt G; Grossmann A; Kirschstein T; Benecke R
    Fortschr Neurol Psychiatr; 2015 May; 83(5):286-9. PubMed ID: 26018396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
    Etcheverry A; Aubry M; de Tayrac M; Vauleon E; Boniface R; Guenot F; Saikali S; Hamlat A; Riffaud L; Menei P; Quillien V; Mosser J
    BMC Genomics; 2010 Dec; 11():701. PubMed ID: 21156036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MGMT Promoter Methylation Status Is Not Related to Histological or Radiological Features in IDH Wild-type Glioblastomas.
    Mikkelsen VE; Dai HY; Stensjøen AL; Berntsen EM; Salvesen Ø; Solheim O; Torp SH
    J Neuropathol Exp Neurol; 2020 Aug; 79(8):855-862. PubMed ID: 32688383
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular profile of long-term survivors of glioblastoma: A scoping review of the literature.
    Gately L; McLachlan SA; Philip J; Rathi V; Dowling A
    J Clin Neurosci; 2019 Oct; 68():1-8. PubMed ID: 31416731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.
    Schulze Heuling E; Knab F; Radke J; Eskilsson E; Martinez-Ledesma E; Koch A; Czabanka M; Dieterich C; Verhaak RG; Harms C; Euskirchen P
    Mol Cancer Res; 2017 May; 15(5):532-540. PubMed ID: 28148826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of
    Kim M; Yoo J; Chang JH; Kim SH
    Anticancer Res; 2022 Jan; 42(1):335-341. PubMed ID: 34969742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
    Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
    PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
    Sturm D; Witt H; Hovestadt V; Khuong-Quang DA; Jones DT; Konermann C; Pfaff E; Tönjes M; Sill M; Bender S; Kool M; Zapatka M; Becker N; Zucknick M; Hielscher T; Liu XY; Fontebasso AM; Ryzhova M; Albrecht S; Jacob K; Wolter M; Ebinger M; Schuhmann MU; van Meter T; Frühwald MC; Hauch H; Pekrun A; Radlwimmer B; Niehues T; von Komorowski G; Dürken M; Kulozik AE; Madden J; Donson A; Foreman NK; Drissi R; Fouladi M; Scheurlen W; von Deimling A; Monoranu C; Roggendorf W; Herold-Mende C; Unterberg A; Kramm CM; Felsberg J; Hartmann C; Wiestler B; Wick W; Milde T; Witt O; Lindroth AM; Schwartzentruber J; Faury D; Fleming A; Zakrzewska M; Liberski PP; Zakrzewski K; Hauser P; Garami M; Klekner A; Bognar L; Morrissy S; Cavalli F; Taylor MD; van Sluis P; Koster J; Versteeg R; Volckmann R; Mikkelsen T; Aldape K; Reifenberger G; Collins VP; Majewski J; Korshunov A; Lichter P; Plass C; Jabado N; Pfister SM
    Cancer Cell; 2012 Oct; 22(4):425-37. PubMed ID: 23079654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
    Morandi L; Franceschi E; de Biase D; Marucci G; Tosoni A; Ermani M; Pession A; Tallini G; Brandes A
    BMC Cancer; 2010 Feb; 10():48. PubMed ID: 20167086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
    Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
    Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
    Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
    Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.